Satelite Symposia

Monday, 18 February

12:00 – 13:15 Schwarzhorn

Satellite Symposium Amgen (a lunch bag will be offered)

PCSK9 Inhibition: Translation of FOURIER into Clinical Practice

Chairman:
T. F. Lüscher, London

12:00 – 12:20

Genetic evidence for the efficacy of PCSK9 inhibition

A. L. Catapano, Milan
12:20 – 12:40

Familial hypercholesterolemia and PCSK9 mutation in patients with ACS

12:40 – 13:00

FOURIER: What does it mean for clinical practice?
Are very low cholesterol levels safe?

F. Mach, Geneva
13:00 – 13:15

Panel discussion

12:00 – 13:15 Seehorn

Update Session Bayer (lunch buffet will be offered)

The horizon of vascular protection and beyond

Chairs:
J. E. Deanfield, London
M. Valgimigli, Berne

12:00 – 12:20

The rise of NOACS in stroke prevention for patients with AFib

A. J. Camm, London
12:20 – 12:40

The rationale for combined platelet and coagulation inhibition

P. G. Steg, Paris
12:40 – 13:00

COMPASS: The new direction in vascular protection

S. Yusuf, Hamilton
13:00 – 13:15

Panel discussion

18:15 – 18:45 Davos 2

Satellite on the Spot Pfizer

How to recognize your cardiac amyloidosis patient

Chairman:
A. V. Kristen, Heidelberg

18:15 – 18:25

What is cardiac amyloidosis?

G. Noll, Zurich
18:25 – 18:35

Diagnostic pathway and red flags

S. Stämpfli, Lucerne
18:35 – 18:45

Recognizing & reaching a differential diagnosis of transthyretin cardiac amyloidosis

A. V. Kristen, Heidelberg